Form 4: NRC Executive Awarded 60,000 Restricted Shares

National Research Corp Executive Vice President Jason Russell Rau was granted 60,000 restricted shares vesting over three years.

Summary

• Jason Russell Rau, Executive Vice President of National Research Corp (NRC), was granted 60,000 shares of common stock.
• The shares are restricted and were issued under the National Research Corporation 2025 Omnibus Incentive Plan.
• The restricted shares will vest in three equal installments on January 1, 2027, January 1, 2028, and January 1, 2029.
• The transaction date for this acquisition was March 12, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive incentive practices and aligning management interests with long-term company performance, without indicating any immediate operational changes.

Positives

• The grant of 60,000 restricted shares to a key executive aligns management incentives with long-term shareholder value.
• The issuance under the 2025 Omnibus Incentive Plan indicates a structured approach to executive compensation and retention.

Negatives

• No immediate negative implications from this Form 4 filing.

Risks

• The value of the restricted shares is subject to the future performance of National Research Corp's common stock.
• Vesting is subject to certain forfeiture and termination provisions, meaning the executive may not ultimately receive all shares if conditions are not met.

Future Outlook

The grant of restricted shares with a multi-year vesting schedule suggests a long-term commitment to the executive and an incentive structure tied to future company performance through 2029.

Management Comments

• No direct management quotes are provided in this Form 4 filing, which is a standard disclosure of insider transactions.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock, are a common practice in the healthcare intelligence and research industry to attract, retain, and incentivize key executives. This aligns the executive's interests with long-term shareholder value, a standard practice among peers.

Comparison to Industry Standards

• Equity compensation packages for executives in the healthcare technology and research sector often include restricted stock units (RSUs) or stock options with multi-year vesting schedules.
• For example, companies like Press Ganey or Health Catalyst frequently utilize similar incentive structures to retain top talent and drive performance.
• The 60,000 shares granted to an Executive Vice President at NRC, with a vesting period extending to 2029, is consistent with typical long-term incentive plans seen in comparable market capitalization companies within the industry, aiming to foster sustained growth and executive alignment.

Corporate Governance

Related Party Transactions

• The transaction involves an executive and the company, which is a related party transaction, but it is a standard compensation event disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant aligns executive incentives with long-term shareholder value, potentially benefiting shareholders if the company performs well. It also represents potential future dilution upon vesting.
• Employees: No direct impact on general employees is indicated, but it highlights the company's executive compensation strategy.

Next Steps

• The restricted shares will vest in three equal installments on January 1, 2027, January 1, 2028, and January 1, 2029.

Key Dates

Recommendation

This Form 4 filing reports a routine executive equity grant, which is a standard compensation practice and does not provide new information significant enough to alter an investment thesis. It reinforces management's long-term alignment but does not indicate any immediate operational or financial catalysts for a 'buy' or 'sell' recommendation.

Keywords

National Research Corp, NRC, Form 4, Restricted Stock, Executive Compensation, Incentive Plan, Jason Russell Rau, Equity Grant